An allogeneic T-cell manufacturer sought the most applicable immunotherapy indication for its lead asset to understand the potential opportunity in the space. Our client engaged LSC to prioritize potential markets based on a number of factors, including market size and route to market entry. LSC worked iteratively with the client to align that the multiple sclerosis market was most attractive and developed a market sizing analysis including shares attributed to specific physician types. A subsequent analysis detailed key features of the path to market and the impact of future pipeline entrants on the market size and share attributable to our client’s product. Ultimately, our client was able to develop a clinical program in the MS space and move their lead asset forward.